Matthew Osborne

Matthew is head of ATP portfolio company investor relations. He brings to this role more than 23 years of biotechnology investor relations, corporate strategic finance, and equity research analyst experience. He has served as chief financial officer of Senda Biosciences, OncXerna Therapeutics, and Unum Therapeutics (now Cogent), where at each of these companies he formulated and implemented financial planning and fundraising efforts as well as scientific and corporate communications and investor relations activities. He has also served as vice president of corporate affairs, communications and investor relations at Voyager Therapeutics, vice president of investor relations and communications at Synageva BioPharma (acquired by Alexion), head of investor relations at Shire Plc (acquired by Takeda) and director of investor relations at Vertex. As a biotechnology sell-side equity analyst at Lazard Capital Markets, Matthew launched several biotech IPOs and analyzed the development of several blockbuster drugs across many therapeutic areas and modalities, having served as an associate analyst previously at Leerink Swann (now SVB Securities).

Matthew earned his BS in Biology from Syracuse University and an MBA from the D’Amore-McKim School of Business at Northeastern University.